IL1RL2 and neoplasm: Consistent with this, two additional models of CRC, one using subcutaneous injection of CT26 cells followed by IP injection of recombinant IL-36Ra and the other using subcutaneous injection of IL-36R knockout CT26 cells, both displayed reduced tumour burden and increased tumour infiltration of CD8+ T cells [85].